Tandem Diabetes Care Cash Flow from Financial Activities 2012-2025 | TNDM
Tandem Diabetes Care cash flow from financial activities from 2012 to 2025. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
| Tandem Diabetes Care Annual Cash Flow Financial (Millions of US $) |
|
|---|---|
| 2024 | $8 |
| 2023 | $4 |
| 2022 | $17 |
| 2021 | $52 |
| 2020 | $314 |
| 2019 | $24 |
| 2018 | $117 |
| 2017 | $40 |
| 2016 | $52 |
| 2015 | $68 |
| 2014 | $4 |
| 2013 | $166 |
| 2012 | $48 |
| 2011 | $13 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $1.331B | $0.940B |
| Tandem Diabetes Care, Inc. designs, develops and markets products for people with insulin-dependent diabetes. The company's flagship product, the t:slim X2 Insulin Delivery System, or t:slim X2, is based on its proprietary technology platform. Per the company, t:slim X2 is the smallest durable insulin pump available and is also the only available pump capable of remote feature updates.Tandem Diabetes also offers t:flex insulin delivery system which includes t:flex pump, its 480-unit disposable insulin cartridge, an infusion set, t:lock cartridge and infusion set products, various pump accessories along with t:slim X2 with G5 integration. | |||